It has been reported that Yupingfengsan can treat ALI by inhibiting TLR4/MyD88 signal pathway and reducing the expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α (57). This evidence concerns the gene TLR4 and acute respiratory distress syndrome.